Species-Specific and Inhibitor-Dependent Conformations of LpxC: Implications for Antibiotic Design  by Lee, Chul-Jin et al.
Chemistry & Biology
ArticleSpecies-Specific and Inhibitor-Dependent
Conformations of LpxC: Implications
for Antibiotic Design
Chul-Jin Lee,1,2 Xiaofei Liang,3,4 Xin Chen,3 Daina Zeng,1 Sang Hoon Joo,1 Hak Suk Chung,1 Adam W. Barb,1,7
Shauna M. Swanson,5 Robert A. Nicholas,5,6 Yaoxian Li,4 Eric J. Toone,1,2,3 Christian R.H. Raetz,1 and Pei Zhou1,2,3,*
1Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA
2Structural Biology and Biophysics Program, Duke University, Durham, NC 27710, USA
3Department of Chemistry, Duke University, Durham, NC 27708, USA
4Department of Chemistry, Jilin University, Changchun, Jilin, People’s Republic of China
5Department of Microbiology and Immunology
6Department of Pharmacology
The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
7Present address: Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA
*Correspondence: peizhou@biochem.duke.edu
DOI 10.1016/j.chembiol.2010.11.011SUMMARY
LpxC is an essential enzyme in the lipid A biosynthetic
pathway ingram-negativebacteria.Several promising
antimicrobial lead compounds targeting LpxC have
been reported, though they typically display a large
variation in potency against different gram-negative
pathogens.Wereport that inhibitorswithadiacetylene
scaffold effectively overcome the resistance caused
by sequence variation in the LpxC substrate-binding
passage. Compound binding is captured in complex
with representative LpxC orthologs, and structural
analysis reveals large conformational differences
that mostly reflect inherent molecular features of
distinct LpxC orthologs, whereas ligand-induced
structural adaptations occur at a smaller scale. These
observationshighlight theneed for amolecular under-
standingof inherentstructural featuresandconforma-
tional plasticity of LpxC enzymes for optimizing LpxC
inhibitors as broad-spectrum antibiotics against
gram-negative infections.
INTRODUCTION
Development of novel antibiotics against multidrug-resistant
gram-negative infections by targeting the UDP-3-O-(acyl)-N-
acetylglucosamine deacetylase (LpxC) in the lipid A biosynthetic
pathway has been a major research focus for industrial groups
and academic laboratories in the last two decades (Barb and
Zhou, 2008; Raetz, 1998; Raetz et al., 2007). Lipid A (endotoxin)
is a glucosamine-based saccharolipid that serves as a hydro-
phobic membrane anchor of lipopolysaccharide (LPS). It is the
major lipid component of the outer leaflet of the outer membrane
of most gram-negative bacteria and shields bacterial cells from
damage by external agents, such as antibiotics and detergents.
Lipid A biosynthesis is an essential pathway in virtually all gram-38 Chemistry & Biology 18, 38–47, January 28, 2011 ª2011 Elseviernegative bacteria, and it starts with the LpxA-catalyzed acylation
of UDP-N-acetylglucosamine (UDP-GlcNAc) (Figure 1A). With
the exception of gram-negative organisms that synthesize lipid
A from the analog UDP-2-acetamido-3-amino-2,3-dideoxy-a-
D-glucopyranose (UDP-GlcNAc3N) (Raetz et al., 2007), the
acylation reaction is thermodynamically unfavorable. Therefore,
the second reaction in the lipid A pathway, the deacetylation of
UDP-3-O-(acyl)-N-acetylglucosamine catalyzed by LpxC, is
generally considered as the committed step of lipid A biosyn-
thesis. Following deacetylation, seven additional enzymes are
needed to synthesize Kdo2-lipid A, the active component of
endotoxin and the LPS substructure sufficient to maintain
bacterial viability.
The lpxC gene is essential and conserved in virtually all
gram-negative organisms. Structural studies of LpxC have re-
vealed a unique protein fold, indicating that highly specific
LpxC inhibitors can be developed as novel antibiotics (Barb
et al., 2007a; Buetow et al., 2006; Coggins et al., 2003, 2005;
Gennadios and Christianson, 2006; Gennadios et al., 2006;
Hernick et al., 2005; Mochalkin et al., 2008; Shin et al., 2007;
Whittington et al., 2003). Consistent with this notion, several
well-characterized LpxC inhibitors (Figure 1B) have been re-
ported to display various degrees of antibiotic activity against
gram-negative bacteria, most notably Escherichia coli (Barb
and Zhou, 2008; Raetz et al., 2007). Very recently, a large number
of LpxC inhibitors with vastly different chemical scaffolds have
appeared in literature (Kline et al., 2002; Pirrung et al., 2003)
and in patent applications (Anderson et al., 2004; Dobler et al.,
2010; Mansoor et al., 2008, 2010; Moser et al., 2008; Raju
et al., 2010; Siddiqui et al., 2007; Takashima et al., 2010;
Yoshinaga et al., 2008); however, the potency and spectrum of
inhibition of these compounds have yet to be systematically
investigated.
Among the well-characterized compounds, CHIR-090 is
the best LpxC inhibitor reported to date, killing both E. coli and
Pseudomonas aeruginosa in bacterial disk diffusion assays
with an efficacy rivaling that of ciprofloxacin (McClerren et al.,
2005). Surprisingly, CHIR-090 is600-fold less effective against
LpxC orthologs from the Rhizobium family than against E. coliLtd All rights reserved
Figure 1. Potent LpxC Inhibitors Block the Committed Step of Lipid A Biosynthesis
(A) LpxC is an essential enzyme that catalyzes the first irreversible step of the lipid A biosynthetic pathway.
(B) Representative LpxC inhibitors.
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Structures of LpxC/LPC-009 ComplexesLpxC (EcLpxC) (Barb et al., 2007b), raising concerns of rapid
evolution of antibiotic resistance for CHIR-090-sensitive strains
through point mutations. Through structural and biochemical
studies of the Aquifex aeolicus LpxC (AaLpxC)/CHIR-090
complex, we have revealed the molecular basis of the intrinsic
resistance of Rhizobium leguminosarum LpxC (RlLpxC) to
CHIR-090 (Barb et al., 2007a) (Figure 2A). These studies showed
that CHIR-090 occupies the hydrophobic substrate-binding
passage consisting of the Insert II region of Domain II in LpxC.
The diphenyl-acetylene group of CHIR-090 penetrates through
this hydrophobic substrate-binding passage, with the first
phenyl group (proximal to the hydroxamate group) located close
to the active site and next to the entrance of the hydrophobic
passage, the acetylene group threading through the narrowest
part of the passage, and the second phenyl ring (distal to the
hydroxamate group) emerging from the passage. The exit of
the substrate-binding passage contains a critical glycine residue
that is conserved in LpxC orthologs sensitive to CHIR-090 inhibi-
tion. In Rhizobium LpxC, however, this critical glycine residue is
replaced by a serine residue, which narrows the exit of the
substrate-binding passage and decreases its susceptibility to
CHIR-090 inhibition by generating van der Waals clashes with
the distal phenyl ring of CHIR-090 (Figure 2A). Consistent with
this notion, a single Ser-to-Gly mutation that broadens the exit
to the substrate-binding passage renders RlLpxC 100-fold
more sensitive to CHIR-090 inhibition, whereas an EcLpxC
mutant with a narrower passage is more resistant to CHIR-090
inhibition compared to the wild-type enzyme (Barb et al.,
2007a). The knowledge that crucial residues in the hydrophobic
substrate-binding passage of CHIR-090-resistant LpxC ortho-
logs can cause van der Waals clashes with the distal aromatic
ring of CHIR-090 motivated us to evaluate novel inhibitors based
on a narrower scaffold for their ability to overcome this resis-
tance mechanism.
Here, we report the biochemical and structural characteriza-
tion of compounds based on the linear diacetylene scaffold.Chemistry & Biology 18,These compounds effectively diminish the resistance of RlLpxC.
Excitingly, the best compound, LPC-009, also shows a general
enhancement of potency (2–64-fold) over CHIR-090 against
a variety of clinically important gram-negative pathogens,
including E. coli, P. aeruginosa, Salmonella typhimurium, Klebsi-
ella pneumonia, Vibrio cholera, Bordetella bronchiseptica, Burk-
holderia cepacia, Burkholderia cenocepacia, and Burkholderia
dolosa. Furthermore, we have captured the binding mode of
LPC-009 in complex with LpxC enzymes from E. coli,A. aeolicus,
and P. aeruginosa. Structural comparison of diverse LpxC
enzymes in complex with the same LPC-009 inhibitor reveals
large, inherent conformational variations of individual LpxC
orthologs and unexpected inhibitor flexibility. The binding of
distinct inhibitors to the same LpxC enzyme also induces notice-
able conformational changes, but at a smaller scale. Thus,
understanding the contribution of inherent molecular features
of representative LpxC enzymes and their associated conforma-
tional dynamics is essential for the design of broad-spectrum
LpxC-targeting antibiotics.
RESULTS
Compounds Based on the Diacetylene Scaffold Potently
Inhibit a Wide Range of LpxC Orthologs
Because point mutations that narrow the LpxC substrate-
binding passage can be a source of antibiotic resistance to
CHIR-090, we reasoned that compounds with a narrower
chemical scaffold—the diacetylene group—would be able to
overcome the CHIR-090 resistance represented by RlLpxC.
The diacetylene scaffold was among the many chemical struc-
tures initially discussed in the international patent WO 2004/
062601 A2 (Anderson et al., 2004), but its effect on the antibiotic
profile was not quantified. To facilitate the analysis, we con-
structed a RlLpxC knock-in strain of E. coli by replacing the
genomic lpxC gene with that of R. leguminosarum (W3110RL)
(Barb et al., 2007b). Because the W3110RL strain is identical to38–47, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 39
Figure 2. Inhibitors Based on the Diacetylene Scaffold Overcome the Resistance Mechanism Represented by RlLpxC and Display Enhanced
Antibiotic Activity
(A) Antibiotic resistance generated by steric clashes between S214 in RlLpxC and the distal ring of CHIR-090. CHIR-090 and the S214 side chain are shown in
stick and transparent-sphere models. The distal phenyl ring of CHIR-090 and the side chain of S214 in RlLpxC are highlighted in red. The Insert II conformation
was generated using homology modeling based on the structure of the AaLpxC/CHIR-090 complex (PDB entry: 2JT2), which contains a Gly (G198) at the
corresponding position of S214 in RlLpxC.
(B) The MICs of each compound against strains of wild-type E. coli (W3110) and E. coli with its genomic lpxC gene replaced by that of R. leguminosarum
(W3110RL). The narrow diacetylene scaffold not only overcomes the CHIR-090 resistance of RlLpxC, but also displays enhanced antibiotic activity against E. coli.
Table 1. MIC Values (mg/ml)
Pathogen
MIC
CHIR-090 LPC-009
Pseudomonas aeruginosa
PAO1
1.6 0.74
Salmonella typhimurium
LT2
0.16 0.024
Klebsiella pneumonia
43816
0.64 0.10
Vibrio cholera
P4 (P27459DctxAB::KmR, SmR)
0.16 0.010
Bordetella bronchiseptica
RB50
16 2.0
Burkholderia cepacia
ATCC 25146
>32 12
Burkholderia cenocepacia
GIIIa J2315 lineage ET12
>32 32
Burkholderia dolosa
AU0158 lineage 5LC6
8.0 0.125
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Structures of LpxC/LPC-009 Complexesthe wild-type E. coli strain W3110 except for the lpxC gene, any
difference in the minimum inhibitory concentration (MIC) values
should directly reflect the different KI values of a compound
against LpxC enzymes, but not other factors such as membrane
permeability. As expected, the MIC values of CHIR-090 are
vastly different for these two bacterial strains, and a 600-fold
variation in MIC values correlates quite well with the KI differ-
ences measured by enzyme kinetic studies (Barb et al.,
2007b). LPC-004, which was identical to CHIR-090 except that
the morpholine moiety was removed, was still significantly less
effective (800 fold) for RlLpxC than for EcLpxC (Figure 2B),
confirming that the bulky distal phenyl group, but not the mor-
pholine group, is responsible for its decreased activity against
RlLpxC. Replacing the phenyl-acetylene group with a (N,N-di-
methylamino)methyl-diacetylene group generated a weaker
inhibitor (LPC-007) for E. coli, but the ratio of the MIC values
for W3110 and W3110RL started to diminish (160-fold). Finally,
addition of a phenyl ring to the diacetylene group (LPC-009)
further reduced the difference of the MIC values between the
two bacterial strains to 126-fold (Figure 2B), suggesting that
the narrow diacetylene group can effectively reduce the intrinsic
resistance of RlLpxC to CHIR-090. Excitingly, LPC-009 also
appears to be 4-fold more potent than CHIR-090 for inhibiting
the growth of E. coli in MIC assays (Figure 2B). To establish
that the diacetylene-based compound LPC-009 indeed displays
a superior antibiotic profile over CHIR-090, we measured
the MICs of LPC-009 and CHIR-090 against a panel of gram-
negative human pathogens, including P. aeruginosa, S. typhimu-
rium, K. pneumonia, V. cholera, B. bronchiseptica, B. cepacia,
B. cenocepacia, and B. dolosa. Invariably, LPC-009 was deter-
mined to be a more potent compound than CHIR-090, showing
a 2–64-fold enhancement of antibiotic activity (Table 1).
To further evaluate the inhibition of EcLpxC by LPC-009,
we performed detailed enzymatic assays. A KI
app of 0.55 ±
0.09 nM and a corresponding KI value of 0.18 ± 0.03 nM were
calculated according to the assumption of competitive inhibition40 Chemistry & Biology 18, 38–47, January 28, 2011 ª2011 Elsevierand a measured KM of 2.5 ± 0.2 mM for EcLpxC (see Experi-
mental Procedures for details). Interestingly, we observed a
similar fractional inhibition of product accumulation with or
without inhibitor preincubation (1 hr) with enzyme prior to initi-
ating the reaction, suggesting that unlike the slow tight-binding
inhibitor CHIR-090, LPC-009 does not appear to inhibit EcLpxC
in a time-dependent fashion.
Overall Structure of EcLpxC in Complex with LPC-009
To probe the molecular details of the LpxC/LPC-009 interaction,
we determined the structure of EcLpxC in complexwith LPC-009
at 1.65 A˚ resolution (crystallographic statistics shown in Table 2).
EcLpxC is the most divergent ortholog to structurally character-
ized LpxC orthologs, such as AaLpxC (34% sequence identity)
and P. aeruginosa LpxC (PaLpxC, 57% sequence identity).Ltd All rights reserved
Table 2. Data Collection and Refinement Statistics
EcLpxC/LPC-009 AaLpxC/LPC-009 PaLpxC/LPC-009
Space group P 61 P 61 P 212121
Cell dimensions
a, b, c (A˚) 90.0, 90.0, 120.0 90.0, 90.0, 120.0 90.0, 90.0, 90.0
a, b, g () 106.7, 106.7, 52.7 65.6, 65.6, 132.3 52.6, 73.6, 88.3
Reflections (unique/total) 41,012/348,669 88,659/662,791 88,611/521,390
Resolution range (A˚) 26.60–1.65 (1.71–1.65)a 23.88–1.25 (1.30–1.25) 22.99–1.28 (1.33–1.28)
Completeness (%) 99.6 (96.6) 100 (100) 99.7 (98.0)
I/s 33.0 (3.3) 23.0 (3.7) 20.8 (2.25)
R-merge (%) 7.4 (49.7) 12.1 (47.1) 11.5 (45.6)
No. of atomsb
Protein 2378 2230 2432
LPC-009 27 27 27
Water 310 455 413
Other molecules 48 12 103
R-factor (%) 17.2 15.4 18.1
R-free (%) 20.2 16.1 19.2
Av. B-factor (A˚2)c
Protein 35.87 14.52 18.00
LPC-009 26.53 19.31 16.68
Catalytic zinc 19.15 11.55 8.75
Water 45.57 31.79 34.19
Rmsd from ideal geometry
Bond lengths (A˚) 0.008 0.004 0.009
Bond angles () 0.924 0.929 0.880
Ramachandran plot
Favored (%) 97.32 97.04 98.25
Allowed (%) 100.00 100.00 100.00
MolProbity
All-atom clashscore 2.51 1.57 1.69
Clashscore percentiled 99th 99th 98th
a Values in parentheses are for highest-resolution shell.
bNonhydrogen atoms. The deposited structures include riding hydrogen atoms used in refinement.
cHydrogen atoms are excluded.
d 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst.
Chemistry & Biology
Structures of LpxC/LPC-009 ComplexesIt is identical to Shigella sonnei LpxC and highly similar to
S. typhimurium LpxC and Yersinia pestis LpxC (>92% sequence
identity). Therefore, E. coli LpxC is an excellent model enzyme
for understanding the behavior of LpxC enzymes from these
clinically important gram-negative pathogens.
EcLpxC consists of two domains with a b-a-a-b sandwich fold
similar to that of AaLpxC or PaLpxC (Figure 3A) (Barb et al.,
2007a; Buetow et al., 2006; Coggins,et al., 2003, 2005; Genna-
dios and Christianson, 2006; Gennadios et al., 2006; Hernick
et al., 2005; Mochalkin et al., 2008; Shin et al., 2007; Whittington
et al., 2003). Each domain contains a layer of helices packing
against a layer of five-stranded b sheet with the helices ‘‘sand-
wiched’’ between the two main b sheets. Additionally, each
domain contains a unique insert region (Insert I of Domain I
and Insert II of Domain II) that adopts a distinct structure. Insert
I forms a small three-stranded b sheet that partially defines the
boundary of the active site, whereas Insert II adopts a babChemistry & Biology 18,structure that forms a topologically closed hydrophobic passage
to harbor substrate or inhibitors.
Consistent with our structure-based prediction, the overall
binding mode of LPC-009 is similar to that of CHIR-090, with
its threonyl-hydroxamate group occupying the active site and
its diacetylene group penetrating through the hydrophobic
substrate-binding passage (Figure 3A). In the active site, the hy-
droxamate group chelates the catalytic zinc ion with a square-
pyramidal geometry (Figure 3B) defined by its two oxygen atoms
and three LpxC residues, H79, H238, and D242. The hydroxa-
mate group is oriented perpendicular to the b strands of Insert
II, and its position is held by hydrogen bonds with the T191
hydroxyl group of Insert II on one side of the active site and the
side chains of the catalytically important residues E78 and
H265 on the opposite side. In addition to these hydroxamate-
mediated interactions, the threonyl moiety of LPC-009 forms
extensive interactions with highly conserved residues in the38–47, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 41
Figure 3. Structure of the EcLpxC/LPC-009 Complex
(A) Overall structure of the complex. EcLpxC is shown in the ribbon diagram and LPC-009 in the space-filling model.
(B) Interactions between LPC-009 and LpxC in the active site.
(C) External view of the hydrophobic substrate-binding passage.
Insert I and Insert II are highlighted in orange and blue, respectively. LPC-009 and selected active site residues are shown in the stickmodel. The active site zinc ion
is shown in the space-filling model. Purple mesh represents 2Fo-Fc map density (contoured at 1.6s) surrounding the LPC-009. The surface plot in panel (C) is
generated by PYMOL (DeLano Scientific LLC).
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Structures of LpxC/LPC-009 Complexesactive site, including (1) van der Waals contacts between its
methyl group and the aromatic ring of F192, which lies at the
base of the active site, and (2) hydrogen bonds between its
amide and hydroxyl groups and the side chains of T191 and
K239, respectively. In addition to these highly conserved interac-
tions, a unique hydrogen bond is observed between the carbonyl
of the carboxyl-amide group of LPC-009 and the backbone
amide of C63 of EcLpxC.
At the entrance of the hydrophobic substrate-binding
passage, the proximal phenyl ring of LPC-009 faces the methyl
groups of L18, and the narrow diacetylene group of LPC-009
penetrates through and emerges from the hydrophobic passage.
Although LPC-009 also contains a distal phenyl ring similar to
CHIR-090, it is located further away from the exit and is less likely
to lead to the possible emergence of antibiotic resistance
through mutation of residues at the exit of the hydrophobic
passage that would clash with the inhibitor. Instead, this distal
phenyl ring of LPC-009 is held by favorable van der Waals
contacts with a hydrophobic ‘‘clamp’’ consisting of residues
outside the substrate-binding passage, including I198, M195,
F212, and V217 (Figure 3C).
Inherent Conformational Differences of LpxC Orthologs
A number of AaLpxC structures in complex with different small
molecules have been reported, revealing an essentially identical
enzyme conformation regardless of the bound inhibitor (Barb
et al., 2007a; Buetow et al., 2006; Coggins, et al. 2003, 2005;
Gennadios and Christianson, 2006; Gennadios et al., 2006; Her-
nick et al., 2005; Shin et al., 2007; Whittington et al., 2003).
However, a distinct orientation of the Insert II helix has been
observed in PaLpxC in complex with BB-78485 (Mochalkin
et al., 2008). Compared to AaLpxC, the PaLpxC Insert II helix
is rotated 16 around a pivot point near the N terminus of the
helix, generating a movement of 7 A˚ at the C-terminal end. It
was proposed that binding to the bulky naphthalene ring of
BB-78485 is responsible for this large conformational difference
(Mochalkin et al., 2008). However, the comparison used different42 Chemistry & Biology 18, 38–47, January 28, 2011 ª2011 ElsevierLpxC orthologs bound to distinct inhibitors, and thus it is not
clear whether the observed structural variation reflects confor-
mational plasticity in response to inhibitor binding or species-
specific differences in the structures of LpxC orthologs, or a
combination of both. The discovery of LPC-009 as a potent
broad-spectrum inhibitor has allowed us to resolve this ambi-
guity by determining and comparing high-resolution structures
of two additional LpxC orthologs, AaLpxC and PaLpxC, in com-
plex with LPC-009 (crystallographic statistics shown in Table 2).
To avoid masking local conformational changes, we superim-
posed the AaLpxC/LPC-009 and PaLpxC/LPC-009 complexes
onto the EcLpxC/LPC-009 complex using only the backbone
Ca atoms of the two main b sheets and four helices that are
highly conserved in sequence and structure across LpxC
orthologs (Figure 4A).
Insert I and Active Site
There are sizeable structural differences in the Insert I region that
partially defines the active site boundary (Figure 4B). All three
LpxC orthologs have Insert I regions with similar lengths and
topologies; however, the three-stranded b sheets contain
b-bulges at different locations. In EcLpxC, the b-bulge is located
after the b-turn connecting the second and third b strands
(bb-bc), whereas in PaLpxC and AaLpxC, the b-bulge is part of
the first strand (ba). Consequently, the ba-strand in EcLpxC forms
the typical interstrandhydrogenbondsofaflatantiparallelbsheet,
whereas the ba-strand in PaLpxC and AaLpxC contains an extra
residue that loopsoutof theplaneof theb sheetand isnot involved
in the main-chain hydrogen bonding network. The EcLpxC loop
connecting ba-bb is one residue longer, pushing it away from
the active site 4.3 A˚ compared to the loop positions of AaLpxC
and PaLpxC (Figures 4A and 4B) and creating a more spacious
active site,with a cavity volumeof 330 A˚3, whereas theactive sites
in PaLpxC and AaLpxC are significantly smaller, with cavity
volumes of 272 A˚3 and 255 A˚3, respectively (Figures 4D–4F).
Insert II Substrate-Binding Passage
Much to our surprise, there are large differences in the orienta-
tion of the Insert II helix in all three LpxC enzymes (EcLpxC,Ltd All rights reserved
Figure 4. Species-Specific Conformational Differences of LpxC Orthologs
(A) Superimposition of EcLpxC/LPC-009 (orange), PaLpxC/LPC-009 (blue) and AaLpxC/LPC-009 (green). The bound LPC-009 is shown in the stick model, and
the catalytic zinc ion in the sphere model.
(B and C) Close-up views around the Insert I and Insert II regions are shown in panels (B) and (C), respectively.
(D–F) The effects of the inherent conformational differences on the size of the active site cavity and the shape and orientation of the hydrophobic substrate-
binding passage, and the bound compound are shown for LpxC enzymes from E. coli, P. aeruginosa, and A. aeolicus in panels (D), (E), and (F), respectively.
Fo-Fc omit map density contoured at 3.4s (blue mesh) is shown around LPC-009 in the bottom panels, illustrating different curvatures of the diacetylene group
of LPC-009 bound to distinct LpxC orthologs. Two conformations of the threonyl group of LPC-009 were used to fit the electron density in the PaLpxC complex,
panel (E).
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Structures of LpxC/LPC-009 ComplexesAaLpxC, and PaLpxC) despite being bound to the same
LPC-009 inhibitor (Figures 4A and 4C). In AaLpxC, the Insert II
helix is positioned closest to the active site, which generates
the widest hydrophobic passage of all three LpxC orthologs
with a diameter of 7.5 A˚. In contrast, the Insert II helix in both
EcLpxC and PaLpxC is rotated 20 around the N-terminal
end of the helix (Figure 4C), moving away from the active site
and resulting in a narrower substrate passage with a diameter
of 4.4 A˚ for EcLpxC and 5.8 A˚ for PaLpxC (Figures 4D and 4E).
The largest difference in the Insert II helix orientation occurs
between EcLpxC and AaLpxC, with the position of the
C-terminal end of the helix deviating by nearly 7.9 A˚. This isChemistry & Biology 18,followed by 5.7 A˚ difference between PaLpxC and AaLpxC,
and 2 A˚ between EcLpxC and PaLpxC (Figure 4A).
In response to the movement of the Insert II helix, LPC-009
also rotates around the threonyl-hydroxamate head group in a
counter clockwise fashion at an angle of 11 in AaLpxC and
3 in PaLpxC compared to its position in EcLpxC (Figures
4D–4F). Interestingly, in contrast to its apparently ‘‘rigid’’
chemical structure, the diacetylene group is slightly curved, a
distortion that has only been previously reported in chemically
constrained diacetylene compounds (Baldwin et al., 1998). The
curvature of the diphenyl-diacetylene group is most prominent
in the AaLpxC complex, followed by the EcLpxC and PaLpxC38–47, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 43
Figure 5. Inhibitor-Induced Structural Plasticity
(A) Superimposition of PaLpxC/LPC-009 (sky blue) and PaLpxC/BB-78485 (pale blue). Binding of LPC-009 and BB-78485 to PaLpxC causes noticeable confor-
mational changes in the Insert I and Insert II regions that generate an open substrate-binding passage accommodating LPC-009 (B), but a closed conformation for
BB-78485 (C). Surfaces of the hydrophobic substrate-binding passage are colored in yellow. Two conformations of the threonyl group of LPC-009 were observed
in the PaLpxC complex.
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Structures of LpxC/LPC-009 Complexescomplexes. This unexpected observation suggests that there is
not a huge energetic penalty for distorting the diacetylene group
to allow for adaptation to the different curvatures of the hydro-
phobic passage in individual LpxC orthologs.
It is important to note that the conformational difference
between AaLpxC/LPC-009 and PaLpxC/LPC-009 is on a similar
scale as the previously reported structural discrepancy between
AaLpxC/TU-514 and PaLpxC/BB-78485 (Mochalkin et al., 2008),
suggesting that the structural divergence in these latter com-
plexes is largely driven by an inherent, species-specific confor-
mational variation, rather than by ligand binding.
Ligand-induced Conformations of LpxC
Our observation of LpxC conformational differences across
orthologs does not rule out the possibility that the enzyme is
able to respond structurally to the binding of distinct inhibitors.
To evaluate the contribution of conformational plasticity to inhib-
itor binding, we compared structures of the same LpxC ortholog
in complex with different inhibitors. Interestingly, superimposi-
tion of AaLpxC/LPC-009 with existing AaLpxC structures shows
very limited conformational variation. On the other hand,
comparison of the PaLpxC/LPC-009 and PaLpxC/BB-78485
(PDB entry: 2VES) structures reveals noticeable conformational
changes in the active site and hydrophobic substrate-binding
passage (Figure 5). These differences are particularly pro-
nounced in the hydrophobic passage: to accommodate the
two bulky and rigid naphthalene groups of BB-78485, the Insert
II helix and its supporting loop (b1-b2 loop) are pushed 2.0–
2.4 A˚ away from the active site compared to the corresponding
structural elements in the PaLpxC/LPC-009 complex. This posi-
tions the Insert II helix closer to the loop immediately following it,
which expands the active site and closes off the hydrophobic
passage in the PaLpxC/BB-78485 complex (Figure 5).
DISCUSSION
The rise of multidrug-resistant microbes and their dire impact on
human health highlight the pressing need for novel antibiotics
with a distinct mode of action to combat gram-negative infec-
tions. Although LpxC is an attractive and validated novel drug
target for these efforts, development of lead compounds has
been hampered by a lack of broad-spectrum antibiotic activity44 Chemistry & Biology 18, 38–47, January 28, 2011 ª2011 Elsevieragainst a wide range of gram-negative bacteria. Here, we detail
a successful strategy for designing a broad-spectrum LpxC
inhibitor: identifying key residues that confer inhibitor resistance
in representative LpxC orthologs and searching for compounds
to circumvent these stumbling blocks. The diacetylene-based
LPC-009 inhibitor presents an important first step in this
process, as our combined kinetic and structural studies show
that LPC-009 inhibits a wide range of orthologs with promising
efficacy. Furthermore, LPC-009 has made it possible to solve
the structure of three LpxC orthologs in complex with a common
inhibitor, including the first structure of the EcLpxC enzyme,
which provides an excellentmodel for several clinically important
pathogens.
In addition to providing the basis for further inhibitor optimiza-
tion, the crystal structures of EcLpxC, AaLpxC, and PaLpxC in
complex with LPC-009 allow us to probe the intrinsic conforma-
tional variability across LpxC orthologs, while avoiding the
contributions from inhibitor-specific conformational changes.
Contrary to the prevailing hypothesis, our study shows that
distinct LpxC orthologs naturally possess large conformational
differences in the Insert II region, which generate distinct shapes
and angles of the hydrophobic substrate-binding passage. It is
important to note that the natural substrate of LpxC is not always
the same; although EcLpxC and PaLpxC utilize acylated UDP-
GlcNAc as a substrate, AaLpxC uses acylated UDP-GlcNAc3N.
The difference of ester versus amide bonds in these substrates
may lead to unique geometrical constraints that may affect their
binding to LpxC (see Figure S1 available online); indeed, different
angles between the acyl chain and UDP moiety have been
observed for R-3-hydroxylauroyl UDP-GlcNAc3N and R-3-hy-
droxymyrisoyl UDP-GlcNAc in the product complexes of LpxA
enzymes from Leptospira species and E. coli, respectively
(Robins et al., 2009; Williams and Raetz, 2007). It seems likely
that the hydrophobic passages of LpxC orthologs are optimized
for processing these distinct substrates, which would partially
explain the inherent conformational differences in the LPC-009
complexes.
The unexpected observation of large, intrinsic structural varia-
tion among LpxC orthologs helps explain the inadequacies of
some of the earlier inhibitors. For example, the unique Insert I
conformation of EcLpxC, wherein the ba-bb loop is pushed
away form the active site to generate an enlarged cavity,Ltd All rights reserved
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EcLpxC by BB-78485: the bulky naphthalene groups of this
compound require a more spacious active site cavity to effec-
tively compete with substrate for binding to the enzyme (Fig-
ure 4D). Consistently, BB-78485 does not bind AaLpxC even at
mM concentrations, and its antibiotic activity toward an E. coli
strain with the native lpxC gene replaced by PaLpxC is at least
20-fold higher than the wild-type E. coli strain (data not shown).
To accommodate the inherent conformational discrepancy of
LpxC orthologs and to achieve a better inhibition profile, an
attractive strategy of inhibitor design is to engineer flexibility
into the chemical scaffold so that the compound can adapt
to the distinct shapes and orientations of the active site and
hydrophobic passage in various LpxC enzymes. A prime
example of this approach is the substrate analog inhibitor
TU-514, which contains a flexible acyl chain occupying the
hydrophobic passage and inhibits a wide range of LpxC
enzymes (Jackman et al., 2000). Interestingly, the diacetylene
group has been observed to adopt ‘‘warped’’ conformations in
chemically constrained compounds (Baldwin et al., 1998), sug-
gesting that the diacetylene group may have a greater intrinsic
flexibility than expected. Given our structural observation of a
distorted diacetylene group in different LpxC enzymes, the
success of LPC-009 may indeed benefit from the ability of the
diacetylene group to adapt to the different trajectories of
the substrate-binding passage in distinct LpxC orthologs.
Despite the similarity between CHIR-090 and LPC-009,
LPC-009 does not appear to display time-dependent inhibition,
whereas CHIR-090 has been shown as a slow, tight-binding
inhibitor for a number of LpxC orthologs. Although the molecular
basis for such difference needs further investigation, it is likely
that the elasticity of the diacetylene bond significantly lowers
the energetic barrier and results in a much faster transition rate
from the initial LpxC/LPC-009 encounter complex to the final
complex, rendering such transition undetectable on the time
scale (seconds to minutes) of enzyme kinetic assays.
A final consideration for inhibitor design is that some LpxC
enzymes may be inherently more flexible than others. For
example, AaLpxC displays a largely rigid structure despite
binding to different small molecules, whereas PaLpxC shows
pronounced ligand-induced conformational changes. A thor-
ough understanding of the structural plasticity of key LpxC
enzymes by probing their dynamic properties in solution may
enable us to design broad-spectrum antibiotics optimized for
the less flexible orthologs, while allowing other LpxC enzymes
to adapt dynamically.
SIGNIFICANCE
The essential LpxC enzyme in the lipid A biosynthetic
pathway is a promising antibiotic target for developing novel
therapeutics against multidrug-resistant gram-negative
pathogens. The majority of LpxC inhibitors discovered so
far display a narrow range of antibiotic activity. This study
presents a structure-based strategy for lead optimization.
We show that compounds based on the diacetylene scaffold
potently inhibit a wider range of LpxC enzymes by over-
coming the resistance mechanism caused by sequence
and conformational heterogeneity in the LpxC substrate-Chemistry & Biology 18,binding passage. The structural revelation of large, inherent
conformational variation of distinct LpxC enzymes and the
relatively small scaleof inhibitor-inducedstructural plasticity
provides a molecular explanation for the limited efficacy of
existing compounds and a rationale to exploit more flexible
scaffolds for further optimization of LpxC-targeting antibi-
otics to treat a wide range of gram-negative infections.
EXPERIMENTAL PROCEDURES
Chemical Synthesis
CHIR-090 and LPC-004were synthesized according to published procedures
(Anderson et al., 2004). Synthesis of LPC-007 and LPC-009 was started from
the acylation of L-threonine methyl ester with sodium 4-ethynylbenzoate.
Under modified Sonogashira coupling conditions (Nicolaou et al., 1982), the
resulting 4-ethynylbenzamide was coupled with substituted acetylene to
afford diacetylene methyl ester. Finally, the methyl ester was converted into
the corresponding hydroxamic acid (LPC-007 and LPC-009) by treatment
with hydroxylamine under basic conditions.
Protein Purification
Plasmids encoding wild-type EcLpxC, PaLpxC (residues 1–299) with a C40S
mutation, and AaLpxC lacking the eight C-terminal amino acids and containing
a C181A mutation (1–274) were prepared following established procedures
(Barb et al., 2007a; Mochalkin et al., 2008). An EcLpxC construct lacking the
C-terminal five amino acids (1–300) was prepared by using the QuikChange
site-directed mutagenesis kit (Stratagene) using a plasmid containing the
full-length EcLpxC as the template. LpxC proteins were overexpressed in
BL21(DE3)STAR cells (Invitrogen) grown in LB media and purified using
anion-exchange (Q-Sepharose Fast Flow, Amersham) and size exclusion
(Sephacryl S-200 HR, Amersham) chromatography. Purified proteins were
concentrated and buffer-exchanged into 25 mM HEPES (pH 7.0) with
100 mM KCl and 0.1 mM ZnSO4. For EcLpxC and PaLpxC proteins, 2 mM
dithiothreitol (DTT) was included in the purification buffers. All protein samples
for enzymatic assay and crystallography were stored at 80C.
Enzymatic Inhibition Assay
UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine and [a-32P]UDP-3-
O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine were prepared and assayed
as previously described (Jackman et al., 2001). Assays of LpxC activity were
performed at 30C in 25 mM sodium phosphate (pH 7.4), 1 mg/mL bovine
serum albumin, 25 mM KCl, and 0.5 mM DTT, in the presence of 5 mM
substrate and 0.2 nM EcLpxC, unless noted otherwise. Ten-percent DMSO
was included and held constant in assay mixtures. Initial velocities were calcu-
lated from the linear portion of reaction progress curves (<10% conversion of
substrate to product).
KM and Vmax values were determined by varying the substrate concentration
from 0.5 to 50 mM. Data were analyzed using an Eadie-Hofstee plot (Dowd and
Riggs, 1965) and by a nonlinear curve-fitting program (KaleidaGraph, Synergy
Software); the resultant values were nearly identical within experimental errors.
To determine a KI value, LPC-009 concentrations were varied from 12.5 pM to
15 nM. Fractional activity (yi/y0) versus LPC-009 concentration was plotted
and fitted to calculate a KI
app value using the Morrison equation (Copeland,
2005):
vi
v0
= 1
½ET + ½IT +KappI

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ½ET + ½IT +KappI
24½ET ½IT
q
2½ET
(1)
where yi is the initial velocity of the reaction in the presence of the inhibitor, y0 is
the initial velocity of the reaction in the absence of the inhibitor, [E]T is the total
enzyme concentration, and [I]T is the total inhibitor concentration. A KI value
was calculated using the following equation:
KI =
KappI
1+ ½S=KM; (2)
where [S] is the substrate concentration. All measurements were done in
triplicates.38–47, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 45
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MICs were determined according to the NCCLS protocol (Wikler et al., 2006)
adapted to 96-well plates and LB media. Briefly, 1.0 3 105 bacterial cells
in LB medium containing 5% DMSO and various concentrations of the
compound were incubated at 37C for 22 hr. After the incubation, [4,5-dime-
thylthiazol-2-yl]-2,5-diphenyltetrazolium bromide solution (MTT) was added
(0.2 mg/mL final concentration) and incubated at 37C for another 3 hr. The
MIC was determined as the lowest concentration of an antibiotic that pre-
vented color change (yellow to black).Crystallization and X-ray Data Collection
Purified EcLpxC (1-300), PaLpxC (1-299, C40S), and AaLpxC (1-275, C181A)
were diluted to final concentrations of 10 mg/mL, 12 mg/mL, and 15 mg/mL,
respectively. For PaLpxC, 10 mM zinc sulfate was added. A four-fold molar
excess of LPC-009 dissolved in DMSO was added to the diluted protein
samples. The protein and inhibitor were incubated at room temperature for
1 hr to obtain a homogenous sample before setting up crystallization
screening. EcLpxC/LPC-009 complex crystals were obtained using the
hanging drop vapor diffusion method at 17C, with the reservoir solution con-
taining 0.1MHEPES (pH 7.5), 1.5 M LiSO4, and 10mMDTT. AaLpxC/LPC-009
and PaLpxC/LPC-009 complex crystals were crystallized using the sitting
drop vapor diffusion method at 20C, with reservoir solutions containing
0.1 M Tris (pH 8.5) and 2.5 M ammonium phosphate dibasic for AaLpxC/
LPC-009, and, 0.1 M sodium acetate trihydrate (pH 5.0) and 2.7 M ammonium
nitrate for PaLpxC/LPC-009. All protein-inhibitor complex samples were
mixed with equal amounts of reservoir solutions and equilibrated against
individual reservoir solutions. The crystals were cryoprotected with perfluoro-
polyether (PFO-X175/08) before being flash-frozen in liquid nitrogen. Diffrac-
tion data were collected at the Southeast Regional Collaborative Access
Team (SER-CAT) 22-BM beamline at the Advanced Photon Source, Argonne
National Laboratory and processed with HKL2000 (Otwinowski and Minor,
1997).Model Building and Refinement
Molecular replacement with the program PHASER (McCoy et al., 2007) was used
to obtain the initial phases of three LpxC-inhibitor complex structures. The
structures of the AaLpxC/TU-514 complex (PDB entry: 2GO4) and the
PaLpxC/BB-78485 complex (PDB entry: 2VES) and a homology model of
EcLpxC derived from the PaLpxC/BB-78485 complex structure were used
as search models for AaLpxC/LPC-009, PaLpxC/LPC-009, and EcLpxC/
LPC-009 complexes, respectively. To avoid phase bias, molecular replace-
ment was performed iteratively, starting from partially refined structures not
containing regions of large structural variations (i.e., Insert I and Insert II).
The EcLpxC/LPC-009 crystal contains an uninterpretable electron density at
the packing interface, which is possibly an impurity from the chemical
synthesis of LPC-009. The excellent quality of the electron density of LPC-
009 allows an unambiguous interpretation of its binding mode in the active
site. Two rotameric conformations of the LPC-009 threonyl moiety were
observed in the PaLpxC complex. Water molecules were added using PHENIX
(Zwart et al., 2008) and verified with COOT (Emsley and Cowtan, 2004). The final
model was obtained after iterative cycles of manual model building with COOT
and refinement using PHENIX. MOLPROBITY (Davis et al., 2007) was used to eval-
uate the quality of the refined structure. The statistics for the three complexes
are shown in Table 1.ACCESSION NUMBERS
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